Tag: HIV

1. This randomized controlled trial (RCT) detected a serological response in significantly more patients who received high-dose Hepatitis B (Hep B) revaccination compared to those who received standard-dose following an initial failed Hep B immunization attempt. 2. After 1 year of follow up, more than double the number of patients...

1. Targeted versus nontargeted HIV screening in the emergency department resulted in a similar number of new HIV diagnoses, yet a lower percentage of testing was performed in the targeted cohorts. Evidence Rating Level: 1 (Excellent) Study Rundown: Diagnosing HIV is a critical public health priority to initiate early treatment and...

1. Dolutegravir-based antiretroviral therapy regimens effectively suppressed maternal viral load during pregnancy, supporting their use to prevent vertical transmission. 2. Dolutegravir, emtricitabine, and tenofovir alafenamide fumarate carried relatively low risk of adverse fetal outcomes. Evidence Rating Level: 1 (Excellent) Study Rundown: Initiation of antiretroviral therapy (ART) for pregnant women infected with HIV-1 is important for...

1. Dolutegravir-based antiretroviral therapy regimens effectively suppressed maternal viral load during pregnancy, supporting their use to prevent vertical transmission. 2. Dolutegravir, emtricitabine, and tenofovir alafenamide fumarate carried relatively low risk of adverse fetal outcomes. Evidence Rating Level: 1 (Excellent) Study Rundown: Initiation of antiretroviral therapy (ART) for pregnant women infected with HIV-1...

1. Patients who switched to tenofovir alafenamide experienced significantly greater increases in weight and lipid levels compared to those who continued tenofovir disoproxil fumarate. 2. The frequency of new-onset diabetes appeared to be similar between groups. Evidence Rating Level: 2 (Good) Study Rundown: Tenofovir is a nucleoside reverse transcriptase inhibitor (NRTi) that...

1. Among virologically suppressed persons with HIV at moderate risk of cardiovascular disease, daily administration of rosuvastatin did not lead to significant reductions in inflammatory markers. Evidence Rating Level: 1 (Excellent) Due to immune dysregulation and chronic inflammation, people with HIV (PWH) have a high burden of cardiovascular disease (CVD) even...

1. At week 48, there was a similar proportion of participants with plasma HIV-1 RNA ≥ 50 copies per mL between the 8-week and 4-week dosing groups. 2. The safety profile was similar between both dosing groups with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Current medications for HIV...

Rosuvastatin therapy in people with HIV at intermediate cardiovascular risk does not decrease biomarkers of inflammation and immune activation 1. Among virologically suppressed persons with HIV at moderate risk of cardiovascular disease, daily administration of rosuvastatin did not lead to significant reductions in inflammatory markers. Evidence Rating Level: 1 (Excellent) Due to...

1. Empiric systemic treatment for tuberculosis was shown not to be better than test-guided treatment among severely immunosuppressed adults with human immunodeficiency virus (HIV) infection. 2. Systemic treatment for tuberculosis was associated with more grade 3 and 4 drug-related adverse events compared to test-guided treatment. Evidence Rating Level: 1 (Excellent) Study Rundown:...

1. In this study, though many adolescent men who have sex with men (AMSM) reported regularly visiting a physician, a much smaller percentage of them reported being tested for HIV or even having conversations with their physician about same-sex behaviors. 2. Simply having a conversation with their physician about HIV...